Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Investigational New Drugs|January 8, 2014
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancerCarolyn D Britten, Alex A Adjei, Robert Millham, et al.Clinical Pharmacokinetics|April 24, 2009
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myelomaDavid I Quinn, John Nemunaitis, Jyotsna Fuloria, et al.Clinical Breast Cancer|March 21, 2009
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten, Richard S Finn, Linda D Bosserman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2009
Resection of thyroid cancer metastases to the sternumJane Yanagawa, Fereidoun Abtin, Chi K Lai, et al.AJR. American Journal of Roentgenology|July 15, 2017
Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 PatientsAntoinette S Gomes, Phillip A Monteleone, James W Sayre, et al.BMC Cancer|January 17, 2012
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot studyCarolyn D Britten, Antoinette S Gomes, Zev A Wainberg, et al.Clinical Colorectal Cancer|January 10, 2017
Racial Differences in Stage IV Colorectal Cancer Survival in Younger and Older PatientsKristin Wallace, Allan DeToma, David N Lewin, et al.Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.Investigational New Drugs|July 15, 2021
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancerChristian Kollmannsberger, Carolyn D Britten, Anthony J Olszanski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsPamela N Munster, Carolyn D Britten, Monica Mita, et al.Pageof 4